The pharmaceutical industry has made a major contribution to global well-being, developing medicines to prevent and treat some of the most difficult diseases. Through constant research and clinical trials, we’ve been able to reach scientific breakthroughs in treating heart failure, multiple sclerosis, and managing some aggressive forms of cancer.

However, as demand for innovation in this industry grows, hurdles such as regulations and rising material costs slow it down. Unfortunately, there are numerous issues that experts in this sector must face, including a talent shortage, rising data security concerns, and resistance to change.

Still, the global use of medicine needs support for growth, which is why technological advancements will help push the industry forward. Here are the top three.

Spectroscopy applications for process monitoring and quality control

Spectroscopy is an advanced tool used in many industries for quality control, including food and beverage and manufacturing. The technology relies on measuring physical characteristics by measuring light intensity at different wavelength ranges, whether visible or near-infrared. A spectrometer uses high-end fibre-optic systems, improving measurements across wavelengths and offering precision in drug development and manufacturing.

In pharmaceutical production, a spectrometer is effective at providing accurate ingredient measurements for purity, detecting impurities, and preventing unusable batches from being manufactured. They benefit the industry by enabling faster operations, real-time monitoring of the manufacturing process, and non-destructive testing in sample analysis.

With techniques like UV-VIS and Raman present in spectrometers from https://www.avantes.com/, the key applications the industry will innovate with include:

• Contributing to the development of new drugs by analysing the molecular structure of potential ingredients, such as organic compounds seen by NMR spectroscopy;
• Leveraging UV-Vis and near-infrared (NIR) spectroscopy for quantifying and controlling the quality of active pharmaceutical ingredients (APIs) in products;
• Monitoring the stability of various products over time under different conditions to detect degradation or impurities;

AI embedding for automation, reallocation, and analysis

Artificial Intelligence is set to be one of the most important factors in the evolution of pharmaceutics, as it can manage a vast array of redundant activities and improve others. AI has already introduced by forward-leading companies that are digitising core processes and connecting multiple networks for efficient operations, such as manufacturing, commercial, and supply chains.

An intelligence tool powered by AI or ML (machine learning) is well-suited for automating tasks such as predictive maintenance, demand forecasting, or anomaly detection. It is also helpful in reallocating resources dynamically according to necessities, navigating the challenges of decision-making.

An interesting application of AI involves analysing large-scale biomedical data to seize the opportunities presented by the use of drugs for a broader array of diseases. Reallocating and repurposing approved drugs for new indications may accelerate the discovery of new treatments at a lower cost. Supervised AI learning can help in:

• Diagnosing diseases or predicting outcomes based on medical data;
• Identifying adverse effects linked with different drugs;
• Predicting safety outcomes or treatment efficacy in clinical trials;

R&D integrations for drug traceability and nanotechnology

Research and development have made substantial contributions to the medical world, but have taken a fairly linear approach from the discovery phase through preclinical research and clinical trials. More modern ways for R&D integration include artificial and human intelligence, and they build on global collaboration. With concentrated effort, R&D can shift the focus of innovation toward under-treated diseases, where what we know as ‘cure’ can be redefined by new knowledge and technology.

There’s a myriad of solutions emerging from internal research capabilities working alongside venture incubators and academic consortia, but most importantly, they’re driving R&D productivity. Some of the closest technologies for R&D include the following:

• Blockchain: these decentralized ledgers can be efficient in tracking the lifecycle and compliance of a drug across the entire supply chain. Benefits address preventing data tampering and reducing the risk of counterfeit drugs;
• Nanotechnology: this solution can improve the outcome of a patient’s treatment by supporting the bioavailability of drugs, in which active ingredients are at their best capacity to reach the desired action in the body;
• 3D bioprinting: creating complex tissue structures can propel R&D results by improving the relevance of preclinical studies;

What should experts in the industry expect in the future?

With fast evolution comes another series of challenges in pharmaceutics. Supply chain management is becoming increasingly difficult, with cybersecurity risks affecting multiple stakeholders and hindering transportation and distribution. The industry is exposed to these attacks because they handle massive amounts of sensitive patient data that are indispensable to the drug supply chain but are, most often than not, inadequately protected.

Whether it’s fraud, industrial espionage, or financial gain, the target in a cybersecurity attack will always have devastating consequences in the system, such as:

• A company’s inability to dispense medicines in time;
• Regulatory sanctions following disruptions in fiscal and social data;
• Considerable financial losses;
• Reputational damage and loss of patient trust;

Is the ageing population presenting new frontiers in pharmaceutics?

The global population is ageing, and we’re seeing new challenges forming for the medical industry. This means the demand for drugs and treatments will not only increase but also require specialized approaches to address the problems posed by current generations’ ageing. While there are opportunities for development, the pharmaceutical sector will have to find other ways to manage chronic illnesses and address the possible changes in human organs that will lead to altered medication. Unfortunately, global life expectancy is increasing, but without the assurance of living a fulfilling and unimpaired life, as new biological changes, such as oxidative stress and climate change, drive these trends.

Final considerations

The pharmaceutical industry is one of the most important for thriving populations, but is increasingly struggling to meet the technological requirements of operating in unstable supply chains and to address new health issues posed by ageing citizens. Luckily, experts rely on advanced technologies such as spectrometry for precise drug management, artificial intelligence to automate tasks, and research and development to advance new testing methods. But businesses must not overlook the risks cyberattacks pose to their reputations and the demanding alterations of drugs for the ageing population.